Buffett and Ives’ Overlap: What Wall Street’s Smartest Money Is Really Betting On

It’s not every day you see Warren Buffett and Dan Ives, the Oracle of Omaha and the Prophet of Palo Alto, quietly loading up on the same trio of stocks. When they do, you’d expect the market to break out in a cold sweat, or at least for the algos to start twitching. Instead, the tape is flat, the volatility is comatose, and the consensus is that nothing matters until the next Fed meeting. But that’s the surface story. Underneath, the convergence of Berkshire Hathaway’s old-school value and Wedbush’s AI Revolution ETF is a signal that the market’s most sophisticated players are quietly recalibrating for a new regime shift.

Let’s start with the news: Buffett and Ives are both betting big on three stocks, according to Benzinga’s latest reporting (2026-04-01). The names aren’t officially disclosed in the snippet, but the overlap is clear enough to send the rumor mill into overdrive. The AI narrative is still burning hot, but the fact that Buffett’s value lens and Ives’ tech optimism are converging should make every trader sit up. This isn’t a meme-stock pile-on or a FOMO-driven chase. It’s a rare alignment of institutional conviction, and that’s the kind of signal that actually moves the needle for fund flows and portfolio construction.

The tape itself is eerily calm. XLK is frozen at $134.95 for four consecutive prints, which is the market’s way of saying, "Wake me up when something breaks." The S&P 500 is rallying on Iran war FOMO, but tech is doing its best impression of a coma patient. Meanwhile, the commodity complex (see DBC at $28.69) is flatlining, and even the usual volatility suspects are missing in action. The only thing moving is the narrative, and right now, the narrative is shifting from "cash is king" to "what’s the next secular winner?"

If you’re looking for context, remember that the last time Buffett and a tech-focused fund manager agreed, it was on Apple, and the rest is trillion-dollar history. But this isn’t 2016. The macro backdrop is a minefield: tariffs are biting, the Iran ceasefire is still just a headline, and the ISM Manufacturing PMI is looming like a storm cloud over May. The market is pricing in a soft landing, but the cracks are showing. Homebuilders and automakers are eating tariff pain, and the wealth effect is starting to bite as the stock market flirts with exhaustion.

So why does this Buffett-Ives overlap matter? Because it’s a rare moment of clarity in a market that’s been defined by confusion and contradiction. When value and growth agree, it usually means the risk/reward is skewed enough to justify taking a shot, even if the tape looks dead. The new Nasdaq IPO rules are a sideshow. The real game is in the names that can survive both a liquidity drought and a tech-driven rotation.

Strykr Watch

Technically, XLK is boxed in a tight range at $134.95. The last time we saw this kind of stasis, it was the calm before a 7% breakout. RSI is hugging the midline, and the 50-day moving average is coiling underneath. The setup is classic: either we get a volatility spike that rips the lid off, or the range resolves lower on a macro shock. Watch for a close above $136 for confirmation of a breakout. Support sits at $132, which is where the last round of institutional buying showed up. If the Buffett-Ives names are in XLK’s top holdings, expect the rotation to accelerate on any sign of life.

The risk, of course, is that the market is sleepwalking into a trap. If ISM PMI prints weak, or if the Iran ceasefire unravels, the entire risk-on thesis could implode. But the technicals say the tape is coiling for a move. The only question is which way.

On the risk side, the bear case is simple: if the macro backdrop deteriorates, tech is still the most crowded trade in the room. A break below $132 opens the door to a fast move down to $128, which is where the last meaningful volume support sits. The risk isn’t in the names themselves, but in the possibility that the market finally wakes up to the fact that tariffs, geopolitical risk, and a slowing economy are a toxic cocktail for high-multiple stocks.

On the flip side, the opportunity is clear: if the Buffett-Ives overlap is a tell, the next move is higher, not lower. The entry is on a dip to $133, with a stop at $131 and a target at $140. If the breakout triggers, the rotation into the top names could be violent, especially if fund managers are sitting on excess cash and looking for a reason to redeploy.

Strykr Take

The market is giving you a rare window to front-run the smart money. When Buffett and Ives agree, it’s not a meme. It’s a signal. Ignore the flat tape and the noise about IPO rules. Focus on the overlap, the technical setup, and the fact that institutional cash is still looking for a home. This is a dip worth buying, but only if you’re willing to cut fast if the macro turns. The real risk isn’t missing the breakout. It’s being caught flat-footed when the regime shifts again.